8月12日，上证指数涨0.5%，收报3665.92点，恒生指数涨0.25%，收报24969.68点。 本文源自：金融界 作者：行情君 资料显示，上海复旦张江生物医药股份有限公司,一九九六年十一月创建于上海浦东张江高科技园区,由 知名企业如上海医药集团股份有限公司等作为公司股东。本着"我们多一分探索、人类多一分健康"的信 念,公司主要从事生物医药的创新研究、开发、生产和销售,力求成为一家以知识产权为核心源泉的生物 医药创新企业。经过多年的不懈努力,公司在基因技术药物、光动力技术药物、纳米技术药物及口服固 体制剂技术药物等领域不断推出新技术及产品,形成了明显的竞争优势,预计未来将陆续有新药投放市 场。凭籍在生物医药领域的实力,公司多次承担"国家重点科技项目(攻关)计划"、"国家高技术研究发展 计划(八六三计划)"、"'重大新药创制'科技重大专项"等。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 复旦张江AH溢价达187.84%，位居AH股溢价率第三位。当日收盘，复旦张江A股报10.52元，跌幅 2.05%，H股报3.99港元，下跌2.68%。 ...

8月12日，上证指数涨0.5%，收报3665.92点，恒生指数涨0.25%，收报24969.68点。 本文源自：金融界 石化油服AH溢价达177.02%，位居AH股溢价率第四位。当日收盘，石化油服A股报2.03元，平盘报收， H股报0.8港元，上涨1.27%。 作者：行情君 资料显示，中石化石油工程技术服务股份有限公司(简称SSC)是中国石化集团公司控股的中国大型的综 合油气工程与技术服务专业公司。拥有超过60年的经营业绩和丰富的项目执行经验,是中国一体化全产 业链油服领先者。2012年6月28日,中国石化集团公司实施石油工程专业化整合重组,将胜利油田、中原油 田、江汉油田、江苏油田、河南油田、华北石油局、西南石油局、华东石油局8家油田企业的石油工程 业务整体剥离,与集团公司总部石油工程管理部及国际石油工程公司、上海海洋石油局整合,成立中石化 石油工程技术服务有限公司。2014年,公司利用仪征化纤上市平台在上海、香港两地同步上市。股票代 码SH600871,HK1033,简称石化油服。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 ...

Group 1 - The Shanghai Composite Index rose by 0.5% to close at 3665.92 points, while the Hang Seng Index increased by 0.25% to 24969.68 points [1] - Zhongyuan Securities' AH premium reached 77.6%, ranking 41st among AH shares [1] - At the close, Zhongyuan Securities' A-shares were priced at 4.49 yuan, with a gain of 0.45%, and H-shares were priced at 2.76 HKD, up by 1.47% [1] Group 2 - Zhongyuan Securities Co., Ltd. was established on November 8, 2002, and is a key player in the capital market development in Henan [1] - It is one of the 140+ securities firms in China that are listed on both the Hong Kong and domestic main boards, having successfully listed in Hong Kong in June 2014 and on the Shanghai Stock Exchange in January 2017 [1] - Zhongyuan Securities has developed into a comprehensive brokerage firm with a focus on research, investment banking, investment business, wealth management, and asset management, ranking 9th in the industry for the number of companies sponsored for listing and approval rate by the end of 2021 [1]

Group 1 - The Shanghai Composite Index rose by 0.5% to close at 3665.92 points, while the Hang Seng Index increased by 0.25% to 24969.68 points [1] - CanSino Biologics has an AH premium of 91.3%, ranking 35th among AH shares. The A-shares closed at 82.5 yuan, down 3.06%, and the H-shares closed at 47.08 HKD, down 6.96% [1] - CanSino Biologics, founded in 2009 in China, focuses on providing innovative, high-quality, and accessible vaccines for the prevention and treatment of infectious diseases, positioning itself as a leading high-tech biopharmaceutical company [1] Group 2 - The company's mission is to provide innovative, high-quality, and accessible vaccines globally, aiming for the vision of "Innovation without end, a world without epidemics" [1] - CanSino Biologics is listed on both the Hong Kong Stock Exchange (H shares, stock code 6185.HK) and the Shanghai Stock Exchange's STAR Market (A shares, stock code 688185), being the first "A+H" vaccine stock since the launch of the STAR Market [1]

Core Points - The Shanghai Composite Index rose by 0.5% to close at 3665.92 points, while the Hang Seng Index increased by 0.25% to 24969.68 points [1] - Longyuan Power's A/H share premium reached 162.6%, ranking sixth among A/H shares [1] - Longyuan Power's A-shares closed at 16.91 yuan, with a gain of 0.24%, and H-shares closed at 7.03 HKD, up by 0.14% [1] Company Overview - Longyuan Power Group Co., Ltd. was established in 1993 and has undergone several ownership changes, currently under the State Energy Group [1] - The company successfully listed on the Hong Kong main board in 2009 and is recognized as "China's first new energy stock" [1] - In 2022, Longyuan Power became the first H-share new energy power generation central enterprise to return to A-shares, marking several firsts in the domestic capital market [1] - Longyuan Power is a pioneer in wind power development in China, leading in offshore, low wind speed, and high altitude wind power sectors [1] - Since 2015, Longyuan Power has maintained its position as the world's largest wind power operator [1]

Company Overview - China Oilfield Services Limited (COSL) is a major integrated oilfield service provider globally, offering services across all stages of offshore oil and gas exploration, development, and production [1] - COSL's business is divided into four main categories: geophysical exploration services, drilling services, oilfield technical services, and marine services [1] Stock Performance - On August 12, the Shanghai Composite Index rose by 0.5%, closing at 3665.92 points, while the Hang Seng Index increased by 0.25%, closing at 24969.68 points [1] - COSL's A-shares closed at 14.01 yuan, with an increase of 0.79%, while its H-shares closed at 7.2 Hong Kong dollars, up by 1.84% [1] A/H Share Premium - COSL's A/H share premium reached 112.43%, ranking it 22nd among A/H shares in terms of premium rate [1][2]

*注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 8月11日，上证指数涨0.34%，收报3647.55点，恒生指数涨0.19%，收报24906.81点。 中远海能AH溢价达63.71%，位居AH股溢价率第57位。当日收盘，中远海能A股报10.17元，跌幅 0.49%，H股报6.79港元，上涨0.44%。 资料显示，中远海运能源运输股份有限公司(股票代码:600026.SH,1138.HK)2016年6月6日成立于上海,是 中国远洋海运集团有限公司旗下从事油品、液化天然气、液化石油气、化学品等储运业务的专业化公 司,由原中国远洋、中国海运两大集团能源运输板块重组而成。公司致力成为全程能源运输方案解决者, 业务覆盖全球300多个港口,为200多家国内外客户提供全船型全天候、定制化服务。中远海运能源聚焦 油轮运输和LNG运输两大核心主业,拥有多年丰富的经验以及较高的品牌知名度,在业界树立了良好的公 司形象。公司油轮船队运力规模世界第一,覆盖全球主流的油轮船型,是全球油轮船队中船型最齐全的航 运公司。 本文源自：金融界 作者：行情君 ...

8月11日，上证指数涨0.34%，收报3647.55点，恒生指数涨0.19%，收报24906.81点。 中海油服AH溢价达114.89%，位居AH股溢价率第21位。当日收盘，中海油服A股报13.9元，跌幅 0.79%，H股报7.07港元，下跌0.28%。 资料显示，中海油田服务股份有限公司(中海油服,China Oilfield Services Limited或COSL)是全球较具规 模的综合型油田服务供应商。服务贯穿海上石油及天然气勘探,开发及生产的各个阶段。业务分为四大 类:物探勘察服务、钻井服务、油田技术服务及船舶服务。COSL于2002年11月20日公开发行H股,并在香 港联合交易所主板上市,股票编号:2883。2004年3月26日起,COSL之股票以一级美国存托凭证的方式在美 国柜台市场进行交易,股票编号为CHOLY。COSL于2007年9月28日在上海证券交易所上市,A股股票简称: 中海油服,股票编号:601808。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 本文源自：金融界 作者：行情君 ...

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **pharmaceutical and medical device industry** in China, particularly the performance and outlook of various companies within this sector [1][2][3]. Core Insights and Arguments - **Medical Device Sector Growth**: The medical device sector is expected to achieve positive growth in the second half of the year, following significant inventory reduction in the first half, leading to a low base effect. Companies like **Mindray Medical** and **United Imaging** are recommended for investment [1][2]. - **International Market Potential**: The domestic market shows steady growth, but overseas markets, particularly in Europe, Asia, Africa, and Latin America, present significant opportunities. Companies such as **Mindray**, **New Industry Bio**, **Nanwei Software**, and **Newmed** are highlighted for their overseas business expansion, expected to show results starting in 2026 [1][5]. - **Traditional Chinese Medicine (TCM)**: The TCM sector is anticipated to improve in Q3 due to low base effects, reduced inventory, and cost improvements, with companies like **Jichuan Pharmaceutical**, **Kweichow Moutai**, and **Shenwei Pharmaceutical** being of interest [1][6]. - **Biopharmaceuticals**: **Ganli Pharmaceutical** is noted for its strong performance in the insulin market, with high likelihood of completing stock incentives. The competitive landscape for insulin weekly formulations is favorable, and companies like **Anke Bio** and **Changchun High-tech** are also recommended [1][6]. - **Innovation in Drug Development**: There is a diversification in funding sources for innovative drug research and development, with a positive trend in both primary market financing and the establishment of industrial funds. The IPO wave for innovative drugs in Hong Kong is expected to surpass the previous cycle, aided by the loosening of listing regulations for unprofitable companies in A-shares [1][8][9]. Additional Important Insights - **Pricing Trends**: The medical device industry has seen a stabilization in pricing, with most products already undergoing centralized procurement. Future price declines are not expected, and the overall pricing environment is becoming more stable [3][4]. - **BD (Business Development) Trends**: The BD upfront payments have become a significant source of funding for R&D in innovative drugs, enhancing companies' willingness to invest in research. The trend indicates a gradual improvement in R&D investment in China [10]. - **Policy Impact**: Recent domestic policies have been favorable for the innovative drug sector, with expectations for more supportive measures to be introduced. The ongoing negotiations for medical insurance in the second half of the year may further reflect this support [12]. - **International Recognition**: Chinese companies are gaining international recognition for their R&D capabilities, leading to substantial BD transactions in areas like ADC and GLP-1 weight loss drugs, indicating a pivotal moment for Chinese innovation on the global stage [13]. - **Performance of Innovative Companies**: Companies like **BeiGene** and **Innovent Biologics** have shown positive earnings trends, with significant upcoming academic conferences expected to provide critical data supporting future BD transactions [14]. Valuation and Market Dynamics - **AH Premium Trends**: The premium for A-shares over H-shares has been narrowing, with leading companies like **Hengrui Medicine** and **WuXi AppTec** showing signs of premium recovery. As of August 1, 2025, Hengrui's AH premium was -10.37%, while WuXi's was 0.40% [15][17]. - **Future Valuation Predictions**: The Hong Kong pharmaceutical sector is still in a valuation recovery phase, with expectations for the AH premium to continue narrowing as Chinese innovative drug companies expand their international presence [19].

龙源电力AH溢价达157.64%，位居AH股溢价率第八位。当日收盘，龙源电力A股报16.54元，涨幅 0.18%，H股报7.02港元，上涨1.01%。 资料显示，龙源电力集团股份有限公司成立于1993年,当时隶属国家能源部,后历经电力部、国家电力公 司、中国国电集团公司,现隶属于国家能源集团。2009年,在香港主板成功上市,被誉为"中国新能源第一 股"。2022年正式在A股上市,成为国内首单H股新能源发电央企回归A股、首单五大发电集团新能源企业 登陆A股资本市场、首单同步实施换股吸收合并、资产出售和资产购买项目。龙源电力是中国最早开发 风电的专业化公司,率先开拓了我国海上、低风速、高海拔等风电领域,率先实现我国风电"走出去",不断 引领行业发展和技术进步。自2015年以来,持续保持世界第一大风电运营商地位。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 本文源自：金融界 作者：行情君 8月7日，上证指数涨0.16%，收报3639.67点，恒生指数涨0.69%，收报25081.63点。 ...